Amgen unveils five-year survival data for Blincyto
Early achievement of complete molecular remission with Blincyto is linked with prolonged survival, researchers note
Read More
Tag: ALL
EU expands use of Amgen’s Blincyto
European regulators have expanded the scope of Amgen’s Blincyto to include the treatment of younger patients with a rare type of leukaemia.
Read More
EU approves first CAR-T therapies
European regulators have approved Novartis’ Kymriah and Gilead’s Yescarta, enabling patients to access CAR-T therapies across the region for the first time.
Read More
Speedy EU, US review for Novartis’ CAR-T therapy Kymriah
Regulators on both sides of the Atlantic are undertaking speedy reviews of Novartis’ CAR-T therapy Kymriah.
Read More
NICE to reassess Pfizer’s leukaemia drug Besponsa
The National Institute for Health and Care Excellence will reassess Pfizer’s Besponsa (inotuzumab ozogamicin) as a treatment for adults with a certain form of leukaemia.
Read More
Novartis files CAR-T therapy in Europe
Novartis has submitted an application to the European Medicines Agency for its CAR-T therapy CTL019 for two haematological indications.
Read More
Novartis’ Kymriah first cell therapy to win US green light
Novartis’ Kymriah has become the first ever CAR-T cell therapy to win approval in the US, bringing paediatric and young adult patients with B-cell acute lymphoblastic leukaemia a novel treatment approach.
Read More
Amgen’s Blincyto wins full US approval
Amgen’s Blincyto has been issued a full approval in the US as a treatment for adults and children with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
Read More
FDA panel backs Novartis’ CAR-T therapy CTL019
Novartis’ CTL019 has taken a giant leap towards the finishing line in the race to get the first cancer killing CAR-T cell therapy on the market having won the support of an FDA advisory panel.
Read More
EU nod for Pfizer’s Besponsa
Pfizer’s antibody drug conjugate Besponsa has become the first to be approved by regulators in Europe to treat some adults with the rare, aggressive cancer acute lymphoblastic leukaemia (ALL).
Read More
NICE rejects Pfizer’s ALL drug Besponsa
The National Institute for Health and Care Excellence has today published draft guidance not recommending Pfizer’s Besponsa to treat some patients with leukaemia on the NHS in England and Wales.
Read More
Novartis’ CAR-T shows durable response in lymphoma patients
Novartis’ closely-watched CTL019 has elicited a strong response in cancer patients taking the experimental CAR-T cell therapy in a mid-stage trial.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
